Bio-Rad Laboratories, Inc. (BIO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Bio-Rad Laboratories, Inc. (BIO) Healthcare & Pipeline Overview

Bio-Rad Laboratories, Inc. is a global leader in life science research and clinical diagnostics, providing reagents, instruments, and software. The company focuses on proteomics, genomics, biopharmaceutical production, and in-vitro diagnostics, serving universities, hospitals, and research institutions across the United States, Europe, Asia, Canada, and Latin America.

What Is the Investment Thesis for BIO?

With a market capitalization of $9.93B and a P/E ratio of 44.27, the company demonstrates financial stability. A gross margin of 51.9% indicates efficient operations. Growth catalysts include expansion in biopharmaceutical production and increasing demand for in vitro diagnostics. Potential risks include competition from firms like Globus Medical, Inc. (GMED) and Align Technology, Inc. (ALGN), as well as regulatory hurdles and technological obsolescence. The company's ongoing investments in innovation and strategic market expansion are expected to drive long-term value.

Based on FMP financials and quantitative analysis

BIO Key Highlights

Market capitalization of $9.93B, reflecting substantial investor confidence.

• P/E ratio of 44.27, indicating a premium valuation based on earnings expectations.
• Gross margin of 51.9%, showcasing efficient cost management and strong pricing power.
• Operates in the life science and clinical diagnostics sectors, providing diversification and stability.
• Employs 7700 people globally, demonstrating significant operational scale.

Who Are BIO's Competitors?

BIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BIO's Key Strengths?

Diversified product portfolio across life science and clinical diagnostics.

• Strong brand reputation and established customer relationships.
• Global presence with sales in multiple regions.
• Consistent investment in research and development.

What Are BIO's Weaknesses?

High P/E ratio may indicate overvaluation.

• Dependence on regulatory approvals for new products.
• Exposure to competition from larger and more diversified companies.
• Potential impact from economic downturns on research spending.

What Could Drive BIO Stock Higher?

BIO catalyst: New product launches in the clinical diagnostics segment, expected to drive revenue growth in Q3 2026.

• Expansion of the company's presence in emerging markets, particularly in Asia and Latin America.
• Continued investment in research and development to drive innovation and maintain a competitive edge.
• Potential acquisitions of companies with complementary technologies or products by Q4 2026.

What Are the Key Risks for BIO?

Rich valuation — a P/E of 44.27 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $5.3M recently.
• Intense competition from established and emerging players in the life science and clinical diagnostics markets.
• Changes in healthcare regulations and reimbursement policies could impact the demand for Bio-Rad's products.
• Technological obsolescence and the need for continuous innovation to maintain a competitive edge.
• Economic downturns and reduced research funding could negatively impact the company's financial performance.

What Are the Growth Opportunities for BIO?

• Expansion in Biopharmaceutical Production: The biopharmaceutical market is experiencing rapid growth, driven by the development of novel therapies and increasing demand for biologics. Bio-Rad's Life Science segment is well-positioned to capitalize on this trend by providing reagents, instruments, and services for biopharmaceutical production processes. This includes products for cell culture, protein purification, and quality control. The global biopharmaceutical market is projected to reach $500 billion by 2028, offering significant growth potential for Bio-Rad. Timeline: Ongoing.
• Increasing Demand for In Vitro Diagnostics: The in vitro diagnostics (IVD) market is driven by the increasing prevalence of chronic diseases, the growing aging population, and the demand for personalized medicine. Bio-Rad's Clinical Diagnostics segment offers a range of test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories. The global IVD market is expected to reach $100 billion by 2027, presenting substantial growth opportunities for Bio-Rad. Timeline: Ongoing.
• Geographic Expansion in Emerging Markets: Emerging markets, such as China and India, are experiencing rapid growth in healthcare expenditure and increasing demand for advanced diagnostic and research tools. Bio-Rad can expand its presence in these markets by establishing strategic partnerships, expanding its distribution network, and developing products tailored to local needs. This geographic expansion can drive significant revenue growth for the company. Timeline: 2-3 years.
• Strategic Acquisitions and Partnerships: Bio-Rad can pursue strategic acquisitions and partnerships to expand its product portfolio, enhance its technological capabilities, and enter new markets. This includes acquiring companies with complementary technologies or products, as well as partnering with research institutions and other companies to develop innovative solutions. These strategic initiatives can accelerate Bio-Rad's growth and strengthen its competitive position. Timeline: Ongoing.
• Focus on Personalized Medicine: Personalized medicine, which involves tailoring medical treatment to individual patients based on their genetic and molecular characteristics, is a rapidly growing field. Bio-Rad can capitalize on this trend by developing diagnostic tools and assays that enable personalized medicine. This includes products for genetic testing, biomarker analysis, and companion diagnostics. The personalized medicine market is expected to reach $200 billion by 2028, offering significant growth opportunities for Bio-Rad. Timeline: 3-5 years.

What Are BIO's Competitive Advantages?

• Strong brand reputation in the life science and clinical diagnostics markets.
• Extensive product portfolio with a wide range of applications.
• Established distribution network and customer relationships.
• Significant investment in research and development.
• Proprietary technologies and intellectual property.

What Does BIO Do?

Bio-Rad Laboratories, Inc., founded in 1952 and headquartered in Hercules, California, is a manufacturer and distributor of life science research and clinical diagnostic products. The company operates through two primary segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments used in research techniques, biopharmaceutical production processes, and food testing regimes. This segment focuses on proteomics, genomics, biopharmaceutical production, cellular biology, and food safety, serving universities, medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, addressing specific niches within the in vitro diagnostics test market. Its products are sold to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Bio-Rad also offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company distributes its products through a direct sales force, as well as through distributors, agents, brokers, and resellers, reaching customers across the United States, Europe, Asia, Canada, and Latin America.

What Products and Services Does BIO Offer?

• Manufactures and distributes life science research products.
• Provides clinical diagnostic products and systems.
• Offers reagents, apparatus, and laboratory instruments for research.
• Develops test systems and informatics systems for clinical laboratories.
• Provides products for proteomics, genomics, and biopharmaceutical production.
• Offers solutions for food testing and safety.
• Develops products for separating, identifying, and analyzing biological materials.

How Does BIO Make Money?

• Develops and manufactures life science and clinical diagnostic products.
• Sells products through a direct sales force and distribution network.
• Generates revenue from the sale of reagents, instruments, and software.
• Provides support and services for its products.

What Industry Does BIO Operate In?

Bio-Rad Laboratories operates in the medical devices industry, which is characterized by continuous innovation, stringent regulatory requirements, and increasing demand for advanced diagnostic and research tools. The global medical devices market is projected to reach $600 billion by 2026, driven by an aging population, rising healthcare expenditure, and technological advancements. Bio-Rad competes with companies like Globus Medical, Inc. (GMED), Align Technology, Inc. (ALGN), and Masimo Corporation (MASI). Bio-Rad's focus on both life science research and clinical diagnostics positions it favorably to capitalize on growth opportunities in both sectors.

Who Are BIO's Key Customers?

• Universities and medical schools.
• Industrial research organizations.
• Government agencies.
• Pharmaceutical manufacturers and biotechnology researchers.
• Food producers and food testing laboratories.
• Reference laboratories, hospital laboratories, and physicians' office laboratories.

Company Profile

Bio-Rad Laboratories, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Hercules, US. The company is led by CEO Norman D. Schwartz. BIO has traded publicly since 1980.

Return on equity for Bio-Rad Laboratories, Inc. stands at 2.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.7%, showing how much profit it generates from its asset base. BIO trades at a trailing price-to-earnings ratio of 44.27, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 4.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.21 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.1%, the inverse of the P/E and a quick read on earnings relative to price.

BIO Valuation & Market Position

With a $9.93B market cap, Bio-Rad Laboratories, Inc. sits in the mid-cap segment of the market. Analyst price targets span from $310.00 to $390.00, with a consensus of $350.00. At the current price of $368.75, that implies roughly 5% downside from the consensus target. Relative to its peer group, BIO's quantitative score of 40/100 is below the peer average of 78/100.

Quarterly Financial Performance: Bio-Rad Laboratories, Inc.

Revenue for Bio-Rad Laboratories, Inc. came in at $651.0M during Jun 2026, a 9.9% improvement versus the preceding quarter. The company recorded net income of $371.4M, with diluted EPS of $13.85. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, BIO averaged $2.06 in diluted EPS.

Bio-Rad Laboratories, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.69 places it in the safe zone, indicating low near-term bankruptcy risk.

Bio-Rad Laboratories, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 22.8% above estimates on average.

Wall Street analysts project Bio-Rad Laboratories, Inc. revenue of about $2.58B for fiscal 2026, with EPS near $9.64. The estimate reflects 4 contributing analysts.

Over the past six months, Bio-Rad Laboratories, Inc. insiders filed 94 SEC Form 4 transactions — 54 sales and 40 purchases. On net that is roughly 38K shares acquired (about $5.3M) — insiders putting money in tends to read as conviction.

BIO Financials

BIO Latest News

BIO Analyst Consensus

BIO MoonshotScore

BIO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources